<DOC>
	<DOCNO>NCT02245542</DOCNO>
	<brief_summary>Study ass efficacy , tolerability safety parameter three month ALNA®OCAS® -treatment special respect nocturia</brief_summary>
	<brief_title>The Impact Alna® Ocas® Nocturia Patients With Lower Urinary Tract Symptoms Suggestive Benign Prostatic Hyperplasia ( LUTS/BPH )</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Nocturia</mesh_term>
	<criteria>Indication treatment ALNA®OCAS® accord prescribe information minimum period three month Patients fulfil one general specific contraindication list ALNA®OCAS® Summary Product Characteristics ( SPC ) , particularly patient know hypersensitivity tamsulosin hydrochloride ingredient product , orthostatic dysregulation severe liver insufficiency could include Post Marketing Study ( PMS ) study</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>